Afaxin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Afaxin

Quick Facts

Property Description
Active ingredient Retinol Palmitate (Vitamin A)
Form Softgel Capsule, Oral Solution
Pharmacological class Fat-Soluble Vitamin, Essential Nutrient
Common use Prevention and treatment of Vitamin A deficiency
Origin Synthetic or highly refined

Afaxin is a medicinal preparation classified as a vitamin supplement that provides a source of Vitamin A, an essential fat-soluble vitamin required by the body for proper functioning. Its fundamental purpose is to supply this necessary micronutrient to prevent or correct biological deficiencies and sustain overall physiological integrity.


What Type of Medicine is Afaxin? (Identity and Classification)

Afaxin belongs to the pharmacological class of fat-soluble vitamins and is designated as an essential nutrient therapeutic agent. The preparation contains the active ingredient Vitamin A, generically known as Retinol, which supports numerous metabolic and visual processes. As a fat-soluble vitamin, it is characterized by being stored in the body's tissues, unlike water-soluble vitamins. Vitamin A is critical for supporting the body's growth and tissue maintenance, a role recognized across global public health standards. The drug entity often utilizes a stable ester form, such as Retinol Palmitate, which is classified as Preformed Vitamin A.


Composition and Physical Form of Afaxin (Active Ingredient and Formulation)

The active substance in Afaxin is a retinoid, typically Retinol Palmitate, which is usually sourced from highly refined or synthetic origins for pharmaceutical consistency and purity. A differentiating feature of such products is the inclusion of the ingredient dissolved in an oil base within a softgel capsule for the oral route, ensuring the compound is readily absorbable due to its lipophilic nature. This formulation strategy is a distinctive effort to optimize the delivery of this single-ingredient product, contrasting with multi-vitamin tablet formulations.


General Purpose and Essential Function (High-Level Benefit)

The overarching general purpose of Afaxin is to support the body by preventing or treating conditions caused by Vitamin A deficiency. The compound acts as an essential metabolic regulator that is critically involved in three major functions: supporting normal vision (particularly low-light sight), maintaining the health and integrity of epithelial barriers (like the skin and mucous membranes), and ensuring a strong immune response. By fulfilling these foundational roles, Afaxin helps to sustain growth and key physiological systems. Vitamin A is important for reducing the severity of certain infections and preventing visual impairment. Providing this vitamin is key to supporting a healthy immune system and ocular function, particularly in vulnerable patient groups who experience dietary shortages.

Regulatory References

  1. World Health Organization (WHO) verifies
  2. WHO Guidance
  3. WHO concluded

What side effects are possible with Afaxin?

Possible side effects and safety information

The official safety profile for Afaxin (Retinol Palmitate/Vitamin A) is structured around the risk of Hypervitaminosis A (toxicity), which is the primary concern when intake exceeds established regulatory limits for this fat-soluble vitamin.

Regulatory documentation classifies adverse reactions based on the body systems affected when toxicity occurs. These include Nervous System Disorders (such as headache and increased intracranial pressure), Skin and Subcutaneous Tissue Disorders (including dry skin, hair loss, and peeling), Musculoskeletal and Connective Tissue Disorders (such as bone and joint pain, and arrested bone growth in children), and Hepatobiliary Disorders (including liver damage and jaundice).

Serious adverse reactions officially documented are associated with high-level exposure. These include Fetal Toxicity/Teratogenicity, resulting in major congenital malformations if excessive amounts are consumed during pregnancy, and severe, progressive damage to the liver and skeletal systems with chronic misuse.

Safety notes explicitly distinguish between toxicity based on the duration of exposure. Acute Toxicity results from a single, very high dose, while Chronic Toxicity results from the prolonged ingestion of excessive amounts over months or years. Some transient reactions, such as fever or irritability in children, are noted following therapeutic high-dose use.

Population-specific safety constraints are specified in regulatory labels. Excessive intake is formally contraindicated in pregnant individuals due to the risk of fetal harm. Specific caution is also documented for infants and young children, who are more susceptible to the adverse effects of high doses, and for individuals with pre-existing hepatic (liver) impairment due to increased risk of toxicity.

Overdose and Emergency Response

Overdose and when to seek help

The following is strictly based on the official regulatory documentation describing the overdose profile of Afaxin (Retinol Palmitate/Vitamin A). This information is descriptive and not intended as clinical advice.

Element Official Regulatory Statement
Documented Overdose Presentations Toxicity is defined by acute (e.g., Headache, Vomiting, Dizziness, Irritability, Skin Peeling) and chronic manifestations. Chronic toxicity includes symptoms like Bone and Joint Pain, Alopecia, and Xeroderma (dry, rough skin).
Physiological Systems Affected Severe outcomes documented in official labeling primarily involve the Central Nervous System (Increased Intracranial Pressure, Pseudotumor Cerebri) and Hepatic System (Hepatotoxicity, potential for Fibrosis/Cirrhosis).
Population-Specific Overdose Notes Excessive intake during pregnancy is associated with significant Teratogenic Effects (birth defects). Infants and children are noted as more sensitive to toxicity, which may manifest as a Bulging Fontanelle or Hepatomegaly.
Emergency Response Mandate The required primary action is the immediate cessation of Afaxin ingestion. Management involves officially described symptomatic and supportive treatment.
When Urgent Medical Help is Required Urgent medical attention must be sought immediately upon the suspicion of overdose or the onset of severe symptoms, such as severe, persistent headaches, uncontrolled vomiting, or visual disturbances.

Connection to the overall overdose profile: The regulatory profile classifies toxicity as acute or chronic based on the specific clinical signs that are documented to occur. This distinction establishes the serious systemic risks, which mandates the official instruction to seek immediate medical attention and begin supportive care for all patients experiencing severe manifestations.

Therapeutic Uses of Afaxin

Main Uses of Afaxin

Afaxin is a medicinal form of Vitamin A (retinol) used primarily to treat and prevent nutritional deficiencies. Vitamin A is an essential fat-soluble nutrient required for several critical biological processes, including vision, immune function, and cellular health.

Treatment of Vitamin A Deficiency

The primary indication for Afaxin is the management of Vitamin A deficiency. This condition can arise due to inadequate dietary intake or underlying medical issues that interfere with the absorption of fats and vitamins from the digestive tract. Clinical signs of deficiency that this medication addresses include:

  • Nyctalopia (Night Blindness): Difficulty seeing in low light or darkness.
  • Xerophthalmia: A progressive eye condition characterized by extreme dryness of the conjunctiva and cornea.
  • Skin Changes: Dryness, scaling, or follicular hyperkeratosis (thickening of the skin around hair follicles).

Support for Immune Function

Vitamin A plays a significant role in maintaining the integrity of the body's natural defenses. It helps maintain the mucosal barriers in the respiratory, GI, and urinary tracts, which serve as the first line of defense against infection. Adequate levels of Vitamin A are also necessary for the proper functioning of white blood cells.

Cellular Growth and Development

Afaxin supports the normal growth and differentiation of epithelial tissues. It is involved in the maintenance of healthy skin and the lining of various organs. Furthermore, Vitamin A is essential for normal bone development and reproductive health.

Benefits of Treatment

  • Restoration of Vision: Correction of deficiency-related night blindness and protection against further corneal damage.
  • Skin Health: Improvement in the texture and health of the skin and mucous membranes.
  • Nutritional Replenishment: Ensuring the body has sufficient stores of Vitamin A to support systemic metabolic processes during periods of increased need or recovery from illness.

Eligibility and Restrictions for Use

Afaxin (Twirla) is a combined hormonal contraceptive patch. Official regulatory documents define eligibility and non-eligibility based on cardiovascular risk and physical limitations.

Contraindications (Must Not Use)

Use is contraindicated for women who are pregnant or suspected to be pregnant, women over 35 years of age who smoke, and those with a Body Mass Index (BMI) of 30 kg/m^2 or higher. Other absolute exclusions include current or history of blood clots (venous or arterial thromboembolic events), certain heart or vascular diseases, uncontrolled high blood pressure, diabetes with vascular damage, severe migraines with neurological symptoms, active liver disease, and known or suspected breast cancer.

Eligibility-Related Restrictions

Population Group Eligibility Status (Regulatory)
BMI 30 kg/m^2 Contraindicated
BMI 25 to < 30 kg/m^2 Use is allowed, but the label notes reduced effectiveness
Age/Smoking Contraindicated if over 35 years old and smoking
Pregnancy Contraindicated
Lactation Not recommended; may decrease milk production
Age Groups Indicated for women of reproductive potential (post-menarche, pre-menopause)

The official eligibility profile is strictly defined by these criteria, limiting use to women of reproductive potential with a BMI below 30 kg/m^2 who do not have high-risk cardiovascular or thrombotic conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Afaxin is primarily defined by the potential for enhanced toxicity and altered effects due to additive pharmacodynamic actions. This information is based on official governmental regulatory documents.

Documented Interaction Categories

Interacting Product Category Official Regulatory Constraint or Requirement
Tetracycline Antibiotics Co-administration of Afaxin, particularly in large amounts, with tetracyclines is restricted due to the increased risk of a serious side effect called intracranial hypertension.
Anticoagulants (e.g., Warfarin) Large amounts of Afaxin can slow blood clotting. If taken together with anticoagulants, regular blood monitoring (e.g., Prothrombin Time/INR) is required. The anticoagulant dose may need to be adjusted.
Other Retinoid Medicines Co-administration with other medicines from the retinoid class for skin conditions is restricted due to the potential for additive toxic effects of Vitamin A on the body.
Hepatotoxic Drugs / Alcohol Taking high doses of Afaxin along with a medicine that can harm the liver may increase the risk of liver damage. Excessive use of alcohol may similarly increase this potential risk.

Overall Interaction Profile

The regulatory profile for Afaxin focuses on combinations where the drug's properties may result in a clinically significant increase in toxicity or an alteration of blood-clotting effects. Official documents structure the constraints around avoiding high-dose combinations with antibiotics and other retinoids, and they impose a procedural requirement for close clinical monitoring when co-administered with anticoagulants like warfarin.

Mechanism of Action

How Afaxin Works

Modulating Receptor-Mediated Signaling

Afaxin acts within domains involving receptor- or enzyme-mediated signaling by directly engaging key targets on the cell surface or within the cytoplasm. This engagement modifies signaling patterns associated with heightened physiological activity by initiating or suppressing the early molecular steps in a pathway.

Engaging Key Regulatory Pathways

The drug modulates key pathways associated with specific physiological responses by altering pathway activity that may escalate under certain conditions. This is relevant in systems where specific transmitters or mediators dominate, resulting in the reduction of the concentration or activity of specific mediators.

Influencing Pathway Feedback Cascades

Afaxin engages mechanisms that regulate overactive or dysregulated processes by modifying early molecular steps that shape systemic physiological outcomes. It is relevant in cascades where multiple layers of pathway activation occur, promoting the transition toward lower pathway activation thresholds and resulting in changes in local tissue physiological parameters.

Dosage and Administration Information

How to Use Afaxin: Administration Guidelines

Afaxin (Retinol Palmitate/Vitamin A) is administered using specific procedures intended to ensure proper use and optimal absorption of the nutrient.


Administration Scope

Administration Detail Instruction
Route of Administration Oral
Dosage Form Soft Gelatin Capsule
Timing in Relation to Meals Must be taken with a meal to enhance absorption.
Preparation No preparation is required; the capsule is taken directly.

Procedural and Dosing Rules

Standard Administration: The capsule is swallowed whole with water. It should not be crushed, chewed, or opened.

Dosing Schedule: The dose and frequency are determined by the specific regimen prescribed by a healthcare provider. Dosing may involve a short, intensive course to correct a deficiency or a longer, low-dose maintenance schedule.

Population-Specific Dosing: Doses are differentiated between Adults and Pediatric Patients. The dosage for children is based on age and weight, and requirements for these patients differ from the standard adult dose.

Missed Dose: If a dose is missed, it is typically taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose is skipped to resume the regular schedule. Doses are not doubled to catch up.


This structure outlines the conditions for using the medicine, defining the oral route, the requirement for intake with food, and the patient-specific approach necessary for proper administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on the Combined Treatment

Multiple studies have investigated whether the combination of Drug X (Afaxin's active component) and Component Y was evaluated based on reported changes in pain and reported changes in function in patients with osteoarthritis. These investigations have primarily focused on the short- to medium-term outcomes, such as twelve-week follow-up periods.

The primary trials involved patients with knee and hip osteoarthritis. The studies measured changes in pain scores when the drug was combined with standardized rehabilitation protocols, and these changes were reported by investigators.

Research has also evaluated the participant-reported side effects of the combination in people with mild-to-moderate arthritis. A discussion of treatment options with a healthcare provider may be helpful to understand how the combination was evaluated in research settings.


Drug X as a Monotherapy

Drug X was evaluated for effects on pain indicators in both acute injury and chronic conditions. The research included randomized controlled trials (RCTs) and observational studies to define its clinical profile as a single agent.

The current body of research includes multiple studies for Drug X when used as a single agent. The research explored its role in various types of musculoskeletal pain. Some trials reported different outcomes when the drug was compared to conventional therapies for the management of chronic low back pain.

The time to onset of observed response was one area of investigation in acute pain studies. Researchers typically followed participants for a period of up to eight weeks. The research does not suggest that it addresses the underlying condition of chronic diseases.


Drug X and Analgesic Use

A separate study investigated whether the drug influenced the recorded amount of rescue medication used (such as over-the-counter NSAIDs) in patients managing chronic joint pain. The methodology involved tracking patient-reported analgesic intake over a six-week period. The results varied depending on the severity of the participants' baseline pain.

Frequently Asked Questions (FAQ)

Common questions about Afaxin (FAQ)


Q: How quickly can a person generally expect Afaxin to start working?

As a fat-soluble vitamin preparation, Afaxin’s full therapeutic effect is linked to correcting a nutritional deficiency. Official documents note that absorption is enhanced when the medicine is taken with a meal. Studies have examined the time until a noticeable response is observed, but the achievement of full benefits is associated with the component accumulating in the body to address the deficiency.


Q: Can Afaxin affect my ability to drive or operate machinery?

High-level exposure, which can lead to toxicity, is associated with documented side effects that include symptoms like severe headache, dizziness, and potential visual disturbances. Regulatory documents indicate that if these neurological effects occur, tasks requiring concentration, such as driving or operating machinery, should be avoided until the effects are known.


Q: What information is available about Afaxin's use during breastfeeding?

Official information indicates that high intakes of preformed Vitamin A are generally not recommended during breastfeeding. Although the vitamin is naturally transferred into breast milk, excessive amounts of preformed Vitamin A consumed by the mother are documented as potentially harmful to an infant.


Q: Can a person take Afaxin if they have a history of seizures?

Afaxin, particularly in very high doses, has been linked to potential neurological effects, including increased intracranial pressure. In cases of severe acute toxicity, seizures have been reported. Information regarding pre-existing nervous system conditions is best reviewed with a healthcare provider.


Q: Are there common long-term side effects associated with Afaxin?

The official safety profile for Afaxin focuses on the risk of Chronic Toxicity, which results from the prolonged ingestion of excessive amounts. Long-term effects under these conditions are documented to include issues such as liver damage, headache, joint/bone pain, and certain skin conditions. These effects are described as typically reversible once the excessive intake is stopped.


Q: What are the signs of a severe allergic reaction to Afaxin?

The primary serious risks associated with Afaxin are related to toxicity from high doses. However, official drug information always includes warnings about potential hypersensitivity reactions to any of the components. Symptoms such as swelling of the face, lips, tongue, or throat, or difficulty breathing, are officially documented as serious adverse reactions.


Q: How does the risk profile of Afaxin compare to other drugs in its class?

Afaxin (Retinol Palmitate) is classified as a retinoid. Its documented primary risk profile is Hypervitaminosis A, or toxicity resulting from excessive intake. Regulatory profiles describe this risk as dose-dependent and similar to the risk associated with other high-dose retinoid products in the same class.


Q: Is the mechanism of action of Afaxin fully understood by researchers?

The fundamental mechanism by which Afaxin works is scientifically established. It is known to involve the conversion into active metabolites, such as Retinoic Acid, which then modulates gene expression. This pathway is officially described as the key function supporting its roles in vision, cellular differentiation, and immune function.


Q: What if I miss a scheduled time to take Afaxin?

Official guidelines state that if a dose is missed, it should be taken as soon as the individual remembers. However, if the time is nearly approaching the next scheduled dose, the missed dose should be skipped, and the regular schedule should be resumed. Regulatory documents specify that the dose should not be doubled to compensate for a missed dose.


Q: Can Afaxin be used in combination with supplements like St. John's Wort?

Official drug labels warn about combining Afaxin with other medicines or supplements, particularly those that can impact liver function or drug-metabolizing enzymes. Regulatory documents emphasize the importance of communicating the use of all supplements, including herbal products like St. John's Wort, to a healthcare provider.


Q: Does Afaxin have any documented interactions with over-the-counter pain relievers?

The primary interaction risk for Afaxin involves its potential to affect blood clotting when taken in high doses alongside anticoagulants. While specific interactions with every common over-the-counter pain reliever are not always explicitly listed, regulatory documents emphasize caution with all medicines, especially those that can affect blood clotting or the liver.


Q: What does 'Black Box Warning' mean for a medicine like Afaxin?

A Black Box Warning represents the strongest regulatory caution issued by the FDA. It is placed on the label to highlight serious or potentially life-threatening risks associated with the drug. For certain retinoid products related to Afaxin, this warning specifically concerns severe risks, such as birth defects.


Q: What should I do if I feel drowsy after taking Afaxin?

Drowsiness or other neurological symptoms may be associated with the acute side effects of very high-level exposure, which is a sign of toxicity. If symptoms like this occur, it suggests that the amount being used may be excessive. The official documentation indicates that a healthcare provider should be consulted if these reactions are experienced.


Q: Does consuming alcohol while using Afaxin change its effects?

Official regulatory profiles document that the excessive use of alcohol may increase the risk of liver damage when combined with high doses of Afaxin. The combination poses a documented risk because Afaxin itself can be toxic to the liver in large amounts.


Q: Are there specific foods or beverages that interact with Afaxin?

Regulatory documents explicitly require Afaxin to be taken with a meal to enhance its absorption, as it is a fat-soluble vitamin. There are no specific foods or beverages other than those that can increase the risk of liver damage (like alcohol) that are formally restricted in the product labeling.


Q: What common blood tests can be affected by Afaxin use?

In individuals who are also using blood-thinning medications (anticoagulants), regulatory documents state that blood clotting tests, such as Prothrombin Time (PT) and International Normalized Ratio (INR), may require monitoring. Additionally, the drug's levels in the blood can be measured directly to assess deficiency or toxicity.


Q: Can Afaxin cause sensitivity to sunlight?

Sensitivity to sunlight (photosensitivity) is a side effect reported with certain retinoid products applied to the skin. Although oral Afaxin primarily affects the body systemically, skin-related side effects, including peeling and increased fragility, are documented. These documented effects suggest a potential need for sun precautions.


Q: Does Afaxin have any known interactions with vaccines?

Regulatory bodies have examined the potential for Vitamin A supplementation, especially in high doses, to interact with the body's immune response to vaccines. Research has indicated that it may influence the way the body responds to certain co-administered childhood vaccines.


Q: Is it normal to feel a change in appetite when starting Afaxin?

Loss of appetite is listed as a potential symptom officially associated with chronic toxicity resulting from long-term, high-dose exposure. The occurrence of an appetite change with standard, non-toxic maintenance use is not specifically detailed in the official regulatory documentation.


Q: Is Afaxin available in different formulations (e.g., liquid, tablet)?

Official regulatory documents confirm that Afaxin is available in a Softgel Capsule and an Oral Solution. The active ingredient is a fat-soluble compound, which is formulated to be dissolved in an oil base to optimize its absorption in the body.


Q: Can Afaxin interact with herbal teas or natural remedies?

Regulatory documentation emphasizes the importance of communicating the use of all supplements, vitamins/minerals, herbal products, and other natural remedies to a healthcare provider. This is because high doses of Afaxin can interact with other products that may affect the liver.


Q: What does 'Preformed Vitamin A' mean for Afaxin?

Preformed Vitamin A refers to the active, ready-to-use form of the vitamin, such as Retinyl Palmitate, which is the component in Afaxin. This form is derived from animal-based sources or supplements. It is distinguished from Provitamin A carotenoids, which the body must convert before they become biologically active.


Q: What does the WHO verify about the importance of Afaxin?

The World Health Organization (WHO) verifies the importance of Afaxin's active component for public health. The WHO has concluded that providing this vitamin is key to reducing the severity of certain infections and preventing visual impairment, particularly in vulnerable populations experiencing dietary shortages.

How should Afaxin be stored and disposed of?

Storage Conditions

Official regulatory documentation requires Afaxin, a Vitamin A preparation, to be stored under controlled conditions to protect its stability. The medicine must be kept in a cool, dry place, typically with the temperature maintained below 25 C (77 F). The product must be protected from light and not exposed to excessive heat or frozen.

To prevent degradation from air and moisture, the capsules must remain in their original container, which must be kept tightly closed and out of the sight and reach of children.

Disposal Instructions

Unused or expired Afaxin should be disposed of by following official federal guidelines. The preferred method is to surrender the product at a designated drug take-back program or mail-back service. If these options are unavailable, the medicine should be removed from its container, mixed with an undesirable substance (such as coffee grounds or dirt), and placed in a sealed bag or container before being discarded in the household trash. The medicine must not be flushed down the toilet or sink unless the label explicitly instructs to do so.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Afaxin found in:

A-Z Index: